About US
Contact us
-
Lonza plagued by supply problems after China plant explosionAn explosion at a chemical plant in China that killed 62 people not only exposed weaknesses in China’s safety oversight but it also exposed weaknesses in the global ingredient supply chain. Thedisrup2019/4/19
-
United Therapeutics teamed with pumpmaker to block Remodulin generics, Sandoz suit saysIt took Novartis' Sandoz years to reach the market with a generic to United Therapeutics’ pulmonary arterial hypertension drug Remodulin, but last month, the company managed to do just that. Now, t2019/4/19
-
Teva CEO Kåre Schultz nabs whopping $33M in first full year at the helmIf you thought Teva had gone big-time with its 2017 pay package for CEO Kåre Schultz, check out what it paid him in 2018. The Israeli drugmakerforked over(PDF) a whopping $32.5 million to its chief e2019/4/18
-
Feds oppose white-coat kickbacks suit out of 'animus' against whistleblowers: judgeA group of whistleblowers made waves in pharma by suing numerous drugmakers, claiming the companiesused nurse educators and other services as kickbacks to boost prescriptions. But insteadof jumping2019/4/18
-
Struggling Insys swaps CEOs as Subsys marketing crackdown continuesInsys has weathered years of litigation, investigations and allegations of illegal sales practices to pump up powerful painkiller Subsys. Now, hoping to revamp its business and its rep, the company2019/4/17
-
Amgen prices bone drug Evenity on par with rival Tymlos, but a tough marketing road lies aheadAmgen is pricing its newly approved osteoporosis drug Evenity on par with Radius Health’s competitor anabolic Tymlos. But its cardiovascular risk has already drawn outcry from a consumer activist gro2019/4/17
-
J&J, under 'accelerating' generic and biosim attack, expects growth to bottom out in 2019Johnson & Johnson's pharma business has been beating the market for years now, but that's about to change. A wave of patent expirations will put a drag on J&J's top-performing unit this year2019/4/16
-
Ionis' Tegsedi gets a U.K. boost after NICE reverses initial guidanceThe path for Ionis’ Tegsedi in the U.K. looked rocky after a preliminary “no” last year from England'sdrug-price watchdog. Fortunately for the drugmaker, that decision was reversed. Tuesday, the Nati2019/4/16
-
AstraZeneca’s Lynparza gets EC approval for breast cancerThe European Commission (EC) has approved AstraZeneca drug Lynparza (olaparib) as a monotherapy to treat locally-advanced or metastatic breast cancer in adults. The drug, which is being co-developed2019/4/15
-
Pfizer to use Concerto HealthAI technology for cancer treatmentsPfizer has partnered with patient-centred research firm Concerto HealthAI to fast-track actionable patient insights for investigational and commercialised cancer therapies. The partnership will lever2019/4/15